Far-UVC efficiently inactivates an airborne pathogen in a room-sized chamber (preprint)

Many infectious diseases, including COVID-19, are transmitted by airborne pathogens. There is a need for effective environmental control measures which, ideally, are not reliant on human behaviour. One potential solution is Far-UVC which can efficiently inactivate pathogens, such as coronaviruses and influenza, in air. When appropriately filtered, and because of its limited penetration, there is evidence that Far-UVC does not induce acute reactions in the skin or eyes, nor delayed effects such as skin cancer. While there is laboratory evidence for far-UVC efficacy, there is limited evidence in full-sized rooms. In the first study of its type, we show that Far-UVC deployed in a room-sized chamber effectively inactivates aerosolised Staphylococcus aureus. At a room ventilation rate of 3 air changes per hour (ACH), with 5 filtered sources the steady-state pathogen load was reduced by 92.1% providing an additional 35 equivalent air changes (eACH). This reduction was achieved using Far-UVC intensities consistent with current regulatory limits. Far-UVC is likely to be more effective against common airborne viruses, including SARS-CoV-2, and should thus be an effective and “hands-off” technology to reduce airborne disease transmission. The findings provide room-scale data to support the design and development of safe and effective Far-UVC systems.

A novel antiviral formulation inhibits a range of enveloped viruses (preprint)

Some free fatty acids derived from milk and vegetable oils are known to have potent antiviral and antibacterial properties. However, therapeutic applications of short to medium chain fatty acids are limited by physical characteristics such as immiscibility in aqueous solutions. We evaluated a novel proprietary formulation based on an emulsion of short chain caprylic acid, ViroSAL, for its ability to inhibit a range of viral infections in vitro and in vivo. In vitro , ViroSAL inhibited the enveloped viruses Epstein-Barr, measles, herpes simplex, Zika and orf parapoxvirus, together with Ebola, Lassa, vesicular stomatitis and SARS-CoV-1 pseudoviruses, in a concentration- and time-dependent manner. Evaluation of the components of ViroSAL revealed that caprylic acid was the main antiviral component; however, the ViroSAL formulation significantly inhibited viral entry compared with caprylic acid alone. In vivo , ViroSAL significantly inhibited Zika and Semliki Forest Virus replication in mice following the inoculation of these viruses into mosquito bite sites. In agreement with studies investigating other free fatty acids, ViroSAL had no effect on norovirus, a non-enveloped virus, indicating that its mechanism of action may be via surfactant disruption of the viral envelope. We have identified a novel antiviral formulation that is of great interest for prevention and/or treatment of a broad range of enveloped viruses.